Humoral Response to COVID-19 Vaccines and Infection during Sibeprenlimab Treatment of IgA Nephropathy Authors: Kieran McCafferty, Jonathan Barratt, Yusuke Suzuki, Adrian Liew, Dana V. Rizk, Bobby Chacko, Laura Kooienga, Richard Lafayette, Muh Geot Wong, Marcela F. Pasetti, Mallory C. Shriver, Kristin Follman, Courtney Moc Willeford, Manisha Sahay, Gerard Honig, Lee Andrews, Lauren E. Olinski, Mohit Mathur, David Oldach Published: 2026 ABSTRACT Visual Abstract Introduction A PRoliferation-Inducing Ligand (APRIL) and B-cell activating factor (BAFF) are cytokines of the TNF superfamily that share functional and structural similarities.1,2 However, they play distinct roles in B-cell biology: BAFF is essential for earlier stages of B-cell maturation and mediates antibody class switching through an independent mechanism through transmembrane activator and calcium-modulator and cyclophilin ligand interactor receptor or BAFF receptor binding, whereas APRIL is an important cytokine in B-cell development, mediating maturation and survival of plasma cells and class switch recombination in B cells through B-cell maturation antigen and transmembrane activator and calcium-modulator and cyclophilin ligand interactor receptor signaling.1–6 APRIL signaling has been identified as an important initiating and sustaining driver in the pathogenesis of IgA nephropathy, a leading cause of CKD, and the most common primary GN worldwide.1,4,7–9 IgA nephropathy is an immune-mediated kidney disease characterized by the deposition of pathogenic galactose-deficient IgA1 (Gd-IgA1)—containing immune complexes in the glomerular mesangium.1,10 Gd-IgA1 serves as an immunogenic epitope in IgA nephropathy, eliciting autoantibodies that drive immune complex formation and glomerular deposition, leading to progressive kidney injury that can result in kidney failure.1,10 By mediating class switching in mature B cells, APRIL supports the production of IgA and pathogenic Gd-IgA1 and may prolong Gd-IgA1–producing plasma cell survival in IgA nephropathy.1 Sibeprenlimab is a humanized IgG2 mAb that selectively blocks the biological actions of APRIL by preventing binding to its receptors.11 In the phase 2 ENVISION trial, sibeprenlimab resulted in significant reductions in 24-hour urine protein to creatinine ratio from baseline at 2, 4, and 8 mg/kg doses (47.2%, 58.8%, and 62.0%, respectively) compared with placebo (20.0%) at 12 months that were sustained through 16 months in the 4 and 8 mg/kg treatment arms. Furthermore, the results demonstrated stabilized eGFR from baseline, reduced hematuria across all dose groups, and decreased levels of serum Gd-IgA1 and IgA compared with placebo.12–14 By selectively inhibiting APRIL without depleting B cells or targeting BAFF, sibeprenlimab is predicted to reduce pathogenic IgA production while preserving essential elements of humoral immunity. In addition to humoral immunity, T-cell–mediated responses are believed to contribute to vaccine-induced protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).15 The selective APRIL inhibition mechanism does not impair T-cell number or function (T-cell–dependent antibody response) as assessed by keyhole limpet hemocyanin in nonhuman primates during treatment with sibeprenlimab.16 In addition, data from the first-in-human trial (NCT03719443) demonstrated that sibeprenlimab did not impair the ability to mount protective recall IgG or IgA responses to tetanus and diphtheria toxoid vaccination, indicating that antigen-specific booster responses were preserved.17 By contrast, broad B-cell–depleting therapies, such as rituximab, may more significantly impair both recall and primary humoral responses (e.g., through B-cell depletion and potential hypogammaglobulinemia), which is believed to contribute to increased susceptibility to severe infections.18–21 During the coronavirus disease 2019 (COVID-19) pandemic, rituximab-treated patients with rheumatoid arthritis had higher rates of severe complications, showing an approximately two-fold higher risk of hospitalization and approximately five-fold higher risk of intensive care unit admission compared with those who received other treatments.22 Rituximab also significantly reduced COVID-19 vaccine seroconversion and markedly diminished serologic response, with instances of seropositivity <20% when administered within 6 months.23 Similarly, the dual APRIL/BAFF inhibitor telitacicept was associated with increased severity of COVID-19 disease in a retrospective review of outcomes in 301 patients with SLE during the second COVID-19 pandemic wave in China,24 suggesting that broader B-cell–targeting approaches may compromise overall humoral immunity. Because APRIL inhibition is of interest as a therapeutic mechanism,25,26 it is important to determine whether selective APRIL inhibition would deleteriously affect primary humoral responses to novel viruses, their vaccines, or infection outcomes. The ENVISION trial, conducted between June 2020 and May 2023, coincided with the global spread of the COVID-19 pandemic (Figure 1), providing a unique opportunity to evaluate the potential impact of sibeprenlimab on immune responses to novel viral antigens and vaccinations.14 During this period, COVID-19 infection presented challenges to naive host immunity, and emerging evidence underscored the critical role of mucosal immunity in protection against SARS-CoV-2. A recent study demonstrated that higher SARS-CoV-2–specific salivary secretory IgA (SIgA) levels after infection were associated with faster viral clearance and rapid symptom resolution, highlighting the importance of mucosal immune responses in controlling infection at the site of viral entry.27 ENVISION enrollment coincided with the global COVID-19 pandemic.28 COVID, coronavirus disease; COVID-19, coronavirus disease 2019; WHO, World Health Organization. Within the ENVISION trial, the incidence and severity of COVID-19 infections during treatment were assessed. An exploratory substudy was conducted to investigate the effects of sibeprenlimab on SARS-CoV-2 vaccine-induced and infection-induced antibody responses. Systemic and mucosal immunity were assessed through serum and salivary antibody measurements to determine whether APRIL inhibition affected circulating antibody and salivary IgA responses. Methods Study Design ENVISION (NCT04287985) was a phase 2, multicenter, double-blind, randomized, placebo-controlled, multiple-dose trial of sibeprenlimab in adults with IgA nephropathy at high risk of progression, treated with intravenous sibeprenlimab (n=117) or placebo (n=38) in addition to optimized background therapy for 12 months.14 Participants were randomized 1:1:1:1 to receive intravenous sibeprenlimab at doses of 2, 4, or 8 mg/kg or placebo once monthly for 12 months. Full study design and results were previously reported.14 The trial was conducted in accordance with the principles of the Declaration of Helsinki and the International Council for Harmonisation Guideline for Good Clinical Practice. The institutional review board or ethics committee for each participating center approved the protocol before initiation of the trial. Participants Inclusion/exclusion criteria for ENVISION were described previously.14 Key inclusion criteria were eGFR ≥30 ml/min per 1.73 m2 and screening 24-hour proteinuria ≥1.0 g/d or 24-hour urine protein to creatinine ratio ≥0.75 g/g.14 Participants were excluded for use of systemic steroids or other systemic immunosuppressive agents within 16 weeks of screening.14 Incidence and severity of COVID-19 infections were reported for all trial participants. An exploratory post hoc analysis of serologic and salivary responses to COVID-19 vaccination and infection was conducted in a subset of consenting participants. Assessments COVID-19 Vaccination and Diagnosis Symptomatic COVID-19 infections (reported as an adverse event [AE]) and COVID-19 vaccination data were recorded for all trial participants. Among substudy participants, symptomatic COVID-19 infection and previously unreported COVID-19 infection (diagnosed retrospectively by serologic analysis) were assessed. Serologic Response to COVID-19 Vaccination and Infection For all substudy participants, monthly serum samples were assessed for antibody titers to SARS-CoV-2 antigens, and all serum antibody concentrations were reported in World Health Organization binding antibody units (BAUs) per milliliter. IgG responses to SARS-CoV-2 spike protein, its receptor binding domain (RBD), and nucleocapsid antigen were assessed. A subset of participants (n=38) with IgG responses to COVID-19 vaccination were further examined for SARS-CoV-2 RBD IgA and IgM responses. All serologic responses were measured against antigens derived from the wild-type Wuhan strain using electrochemiluminescence immunoassays from the Meso Scale Discovery V-PLEX platform; the specific SARS-CoV-2 strains infecting participants were not assessed in this analysis. A protective, albeit arbitrary, threshold of 300 BAU/ml for IgG-RBD was used here on the basis of prior analysis of large COVID-19 vaccine datasets,29 to provide a framework for analyses. Additional methods and definitions for assessment of serologic diagnosis or infection, antibody titers, and participant COVID-19 status (e.g., naive, vaccinated, postinfection) are in Supplemental Methods. An example serologic profile over time is presented in Supplemental Figure 1. Salivary IgA Response to COVID-19 Infection or Vaccination Saliva samples were examined for IgA-RBD at baseline, month 6, and month 12 using a Meso Scale Discovery electrochemiluminescence immunoassay. Additional details for measuring salivary IgA-RBD can be found in Supplemental Methods. For this retrospective analysis, 47 participants had saliva samples available for analysis, with 23 having a sample collected within 4–16 weeks after identified infection or vaccination for postinfection or postvaccine antibody response analysis, respectively. Flow Cytometry Analysis of B-Cell Subsets and T Cells Circulating immune cell populations were analyzed using flow cytometry panels targeting B-cell class switching and T cells, B cells, and natural killer cells. A TruCount tube containing CD45 peridinin-chlorophyll-protein complex was stained in parallel to enable calculation of absolute cell counts. Whole blood was collected from all participants in the ENVISION trial into CytoChex blood collection tubes at baseline, month 6, month 12, and month 16. Total B cells, total T cells, and B-cell subsets (including naive, memory, switched memory, and plasmablast) were reported by dosing group as median fold change from baseline (in absolute cell counts) and as frequency over time. Further details for cell staining and data analysis can be found in Supplemental Figure 2 and Supplemental Methods. Statistical Analysis Sibeprenlimab-treated participants were pooled across all dose levels (2, 4, and 8 mg/kg) to achieve a sufficiently large sample size. Statistical analysis was performed on IgG-RBD peak titers (t test) because data from a sufficient number of participants were available. Results of t tests are also presented for IgA-RBD and IgM-RBD peak titers; however, these should be interpreted with caution owing to the small sample sizes and limited statistical power. Slopes of IgG-RBD decline curves were used to generate estimates of time above a protective threshold when there were ≥2 points from the maximum titer available. A Welch two-sample t test was applied to log-transformed peak IgG-RBD titers for significance testing. Antibody titers are presented as geometric means with 95% confidence intervals (CIs) because data are not normally distributed. Results Participant Population Of the 155 randomized participants in ENVISION, 117 received sibeprenlimab (2 mg/kg, n=38; 4 mg/kg, n=41; 8 mg/kg, n=38) and 38 received placebo.14 ENVISION baseline characteristics were generally similar among the cohorts (details reported previously).14 The substudy included 72 participants (sibeprenlimab n=52; placebo n=20). Demographic and baseline characteristics are shown in Supplemental Table 1. Anti–SARS-CoV-2 spike protein antibody titers did not differ significantly from anti-RBD profiles; therefore, data presentation is limited to RBD titers. COVID-19 Diagnoses and Severity Across all participants in ENVISION, symptomatic COVID-19 diagnosis rates (reported as AEs) were comparable in pooled sibeprenlimab (33.3%; 39/117) and placebo (44.7%; 17/38) recipients (Table 1). Most of the COVID-19 AEs were of mild severity, regardless of sibeprenlimab dose or placebo. Two participants (sibeprenlimab, n=1; placebo, n=1) were hospitalized with serious COVID-19 AEs; none were admitted to intensive care or mechanically ventilated, and there were no COVID-19–related deaths. When COVID-19 infection could be ascertained serologically in substudy participants, 61.5% (32 of 52) and 70.0% (14 of 20) of sibeprenlimab and placebo recipients, respectively, had any COVID-19 diagnosis (symptomatic and/or retrospectively serologically diagnosed). The proportion of participants with any previously unreported, serologically diagnosed COVID-19 infection was greater for sibeprenlimab (30.8%; 16 of 52) compared with placebo (10.0%; 2 of 20). Table 1Coronavirus disease 2019 diagnosis and severityParameterSibeprenlimabPooled SibeprenlimabPlacebo2 mg/kg4 mg/kg8 mg/kg Entire study n=38n=41n=38n=117n=38 COVID-19 AE, n (%)a11 (29)12 (29)16 (42)39 (33)17 (45) Mild10 (26)12 (29)13 (34)35 (30)16 (42) Moderate003 (8)3 (3)1b (3) Severe1b (3)001 (1)0 COVID-19 substudy, n (%) n=22n=17n=13n=52n=20 COVID-19 AEa,c8 (36)4 (24)7 (54)19 (37)13 (65) Serologic diagnosis of COVID-19c,d7 (32)5 (29)4 (31)16 (31)2 (10) Any COVID-19 diagnosise14 (64)9 (53)9 (69)32 (62)14 (70)AE, adverse event; COVID-19, coronavirus disease 2019.aParticipants with two events were counted only once, with greatest severity recorded.bCategorized as a serious adverse event.cParticipants in the COVID-19 substudy with both COVID-19 adverse event and serologic diagnosis of COVID-19 events are counted in both categories.dRetrospective serologic diagnosis, not reported as an adverse event.eIncludes adverse event and serologic diagnoses (possible for substudy participants only). Participants with both adverse event and serologically diagnosed COVID-19 events were counted only once in the “any COVID-19 diagnosis” category. Coronavirus disease 2019 diagnosis and severity AE, adverse event; COVID-19, coronavirus disease 2019. Participants with two events were counted only once, with greatest severity recorded. Categorized as a serious adverse event. Participants in the COVID-19 substudy with both COVID-19 adverse event and serologic diagnosis of COVID-19 events are counted in both categories. Retrospective serologic diagnosis, not reported as an adverse event. Includes adverse event and serologic diagnoses (possible for substudy participants only). Participants with both adverse event and serologically diagnosed COVID-19 events were counted only once in the “any COVID-19 diagnosis” category. Serologic Response to COVID-19 Vaccination Serologic responses to COVID-19 vaccination in participants who were COVID-19–naive at the time of primary vaccination with a two-dose mRNA vaccine (BNT162b2 [Pfizer] or 1273 [Moderna]) are shown in Figure 2. After primary vaccination, COVID-19 seroconversion rates were 100% for serum IgG antibodies against SARS-CoV-2 RBD among all trial participants. Peak IgG-RBD antibody titers after primary vaccination were not statistically different (P = 0.13) between placebo and pooled sibeprenlimab groups; geometric means (95% CI) were numerically higher in the placebo group (3968 [2430 to 6480] BAU/ml) than in the pooled sibeprenlimab group (1921 [1196 to 3086] BAU/ml). Importantly, IgG-RBD antibody titers were above the 300 BAU/ml threshold in all participants who received sibeprenlimab, similar to placebo recipients. Among COVID-19–naive participants who received primary COVID-19 vaccination, peak serum IgA-RBD, and IgM-RBD titers during sibeprenlimab treatment (geometric means [95% CI], 329 [135 to 806] and 18 [7 to 43] BAU/ml, respectively) were reduced compared with placebo (1451 [486 to 4338] and 39 [18 to 83] BAU/ml, respectively), consistent with the approximately 65%–75% reduction in total IgA and IgM associated with sibeprenlimab administration (Figure 2).14 Despite reductions in peak titer values, most of the sibeprenlimab recipients mounted SARS-CoV-2–specific serum IgA and IgM responses after vaccination, with 91% (ten/11) and 73% (eight/11) of sibeprenlimab recipients having peak IgA-RBD and IgM-RBD titers greater than the geometric mean of the prevaccination titer, respectively. Serologic response to COVID-19 vaccination in COVID-19–naive participants. Peak IgG, IgA, and IgM antibody titers to SARS-CoV-2 RBD after a two-dose mRNA vaccine in immunologically naive participants. n=number of discrete event occurrences (one person may have more than one event). Horizontal dashed line indicates the protective threshold (300 BAU/ml). BAU, binding antibody unit; CI, confidence interval; RBD, receptor binding domain; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. In COVID-19–naive participants, the durability of the elicited IgG-RBD response after primary mRNA vaccination was similar between sibeprenlimab and placebo recipients (Figure 3). The median duration above the 300 BAU/ml threshold was 169 (range, 66–449) days among sibeprenlimab recipients (n=14) and 134 (range, 104–351) days among placebo recipients (n=9). Duration of serologic response to COVID-19 vaccination in COVID-19–naive participants. Duration of the IgG antibody to SARS-CoV-2 RBD response after a two-dose mRNA vaccine in immunologically naive participants. Horizontal dashed line indicates protective threshold (300 BAU/ml). CV, coefficient of variation. Serologic responses to any COVID-19 primary vaccination (including mRNA, adenoviral vector, and inactivated virus; see Supplemental Table 2) and/or boosters in participants irrespective of prior COVID-19 exposure (i.e., COVID-19 naive and experienced) are shown in Supplemental Figure 3. Peak IgG-RBD antibody titers after any COVID-19 vaccine and/or booster event were comparable between pooled sibeprenlimab (geometric mean [95% CI], 1922 [1169 to 3161] BAU/ml) and placebo groups (3509 [1957 to 6290] BAU/ml), with no statistically significant difference (P = 0.43). Among COVID-19–naive or COVID-19–experienced participants who received primary vaccination and/or booster, peak serum IgA-RBD, and IgM-RBD titers in participants treated with sibeprenlimab (IgA-RBD geometric mean [95% CI], 268 [140 to 513] BAU/ml; IgM-RBD geometric mean, 9 [5 to 17] BAU/ml) were reduced compared with placebo (IgA-RBD, 1249 [590 to 2644] BAU/ml; IgM-RBD, 30 [17 to 53] BAU/ml), but IgA and IgM responses to SARS-CoV-2 RBD were still induced in the sibeprenlimab-treated group. Serologic Response to COVID-19 Infection Serologic responses to symptomatic COVID-19 infection (reported as AE) in COVID-19–experienced participants are shown in Figure 4. Peak IgG-RBD antibody titers after COVID-19 infection were comparable between placebo and sibeprenlimab, and all were above the 300 BAU/ml threshold. IgG-RBD geometric mean (95% CI) titer was 4572 (2209 to 9459) BAU/ml in sibeprenlimab recipients and 6541 (3394 to 12,607) BAU/ml in placebo recipients, with no significant difference between the values (P = 0.85). Among COVID-19–experienced participants who had symptomatic COVID-19 infection, serum IgA-RBD and IgM-RBD peak responses were induced to COVID-19 infection in both groups, with trends toward lower peak responses with sibeprenlimab (IgA geometric mean [95% CI], 1411 [408 to 4883] BAU/ml; IgM, 6 [2 to 19] BAU/ml) compared with placebo (IgA, 4669 [1010 to 21,577] BAU/ml; IgM, 9 [4 to 19] BAU/ml). Serologic response to COVID-19 infection reported as an AE in COVID-experienced participants. Peak IgG, IgA, and IgM antibody titers to SARS-CoV-2 RBD after COVID-19 infection, identified as an AE, in immunologically non-naive participants. n=number of discrete event occurrences (one person may have more than one event). Horizontal dashed line indicates the protective threshold (300 BAU/ml). AE, adverse event. Serologic responses to any COVID-19 infection (reported as AEs or serologically diagnosed) irrespective of prior COVID-19 exposure are shown in Supplemental Figure 4. Peak IgG-RBD titers after COVID-19 infection were comparable between placebo and sibeprenlimab groups, and all IgG-RBD titers in sibeprenlimab-treated participants were above the 300 BAU/ml threshold. IgG-RBD geometric mean (95% CI) titer was 3360 (2277 to 4957) BAU/ml in sibeprenlimab recipients and 7113 (4092 to 12,362) BAU/ml in placebo recipients, with no statistically significant difference between the groups (P = 0.29). Among COVID-19–naive and COVID-19–experienced participants who had a COVID-19–related AE or serologically diagnosed infection, IgA-RBD and IgM-RBD responses were induced after COVID-19 infection in both groups, with trends toward lower peak responses in the sibeprenlimab group (IgA geometric mean [95% CI], 499 [229 to 1087] BAU/ml; IgM, 6 [3 to 10] BAU/ml) compared with placebo (IgA, 3498 [875 to 13,987] BAU/ml; IgM, 11 [5 to 24] BAU/ml). In COVID-19–naive and COVID-19–experienced participants with any COVID-19 infection, there was no correlation between pre-existing IgG-RBD antibody levels (to the Wuhan strain) before infection and either a symptomatic or an asymptomatic diagnosis in participants who received placebo or sibeprenlimab (Supplemental Figure 5). Notably, given the timing and geography of enrollment, it is unlikely that most of the infections observed in the trial were caused by the Wuhan strain. Mucosal Immunity: Salivary IgA-RBD Response to COVID-19 Infection Owing to the variability in infection and vaccination timing and the unclear kinetics of SARS-CoV-2–specific IgA in saliva, saliva samples that were collected in a time-restricted window of 4–16 weeks post–COVID-19 vaccine or infection were examined for COVID-19–specific antibodies (Supplemental Table 3). As expected from an intramuscular vaccination, postvaccination anti–SARS-CoV-2 RBD salivary IgA responses were not robust for either placebo or sibeprenlimab recipients,29 but salivary IgA-RBD was detected after COVID-19 infection among all tested participants. Although the geometric mean of the ratioed response was lower in sibeprenlimab-treated participants compared with placebo-treated participants, the median fold change in salivary IgA-RBD/SIgA seemed to be similar between both groups, suggesting that salivary IgA-RBD is induced in response to COVID-19 infection in the context of sibeprenlimab treatment (Figure 5 and Supplemental Table 3). Salivary IgA-RBD after COVID-19 infection. Salivary IgA antibody to SARS-CoV-2 RBD over the total salivary SIgA in samples that were within 4–16 weeks after any COVID-19 infection. AU, arbitrary units; SIgA, secretory IgA. Peripheral B-Cell Subsets Immune cell examination through longitudinal flow cytometric analysis was performed on all trial participants at select time points. There were no robust changes in total B or T cells or in B-cell subsets—including naive, memory (total or switched), and plasmablast—measured as median fold change from baseline (absolute count) or as frequency over time for any sibeprenlimab dose or placebo (Figure 6 and Supplemental Figure 6). B-cell subsets and T cells. B-cell subsets (total B cells, naive B cells, memory B cells, plasmablasts, and switched memory B cells) and T cells over time by sibeprenlimab dose or placebo group. Data in the tables represent the number of participants in each dosing group at each assessed time point. Values are median fold changes from baseline in absolute cell counts over time. Error bars indicate interquartile ranges. Vertical dashed lines indicate end of study treatment period at day 360 (month 12). Abs, absolute; BCT-CL, blood collection tube – cell ontology; CL, cell ontology. Discussion This exploratory substudy analysis from the ENVISION trial was opportunistically performed in response to an unexpected and profoundly disruptive event: the onset of the global COVID-19 pandemic. The results provide unique and important insights into the effects of APRIL inhibition on host responses to infection and support the hypothesis that sibeprenlimab may preserve important components of humoral immunity while effectively reducing proteinuria and stabilizing eGFR in adults with IgA nephropathy. To our knowledge, this is the first clinical investigation of humoral responses to de novo viral vaccination and infection in humans treated with a selective APRIL inhibitor. Sibeprenlimab did not substantially impair serum or saliva antibody responses to clinically meaningful viral antigens from SARS-CoV-2. During sibeprenlimab treatment, seroconversion rates of 100% for IgG-RBD were observed, peak IgG-RBD titers postvaccination exceeded a threshold of 300 BAU/ml, and IgG-RBD duration was similar to that for placebo after primary mRNA vaccination in all COVID-19–naive participants. SARS-CoV-2–specific IgG responses to infection were also preserved. Although IgG-RBD antibody titers are important for humoral COVID-19 immunity,30 these data suggest that preexisting IgG-RBD levels may not have a strong correlation with infection or presentation as symptomatic (AE) or asymptomatic (serologic diagnosis) COVID-19 in this clinical context. The early humoral response to SARS-CoV-2 is characterized by the rapid production of both IgM and IgA antibodies. Although both contribute to viral control, IgA targeting the RBD has been identified as a potent neutralizer. This enhanced neutralizing capacity is particularly significant for IgA at mucosal sites, which provides a first line of defense against infection.31,32 Salivary IgA-RBD detection in this analysis suggests that this important element of mucosal immunity remained preserved despite the systemic IgA (and IgM and IgG) reductions observed with sibeprenlimab.14,17 In addition, COVID-19–specific IgA and IgM vaccine, infection, and antibody responses were still mounted in the majority of participants receiving sibeprenlimab, although the average response levels were lower than those observed in the placebo group. The sample sizes for all analyses and particularly for IgA and IgM were relatively small, and the P values for differences between groups should not be overinterpreted. Reported data from APRIL/BAFF inhibitors have not included investigation of responses to de novo vaccination, whereas these novel findings support the hypothesis that patients with IgA nephropathy can form immune responses to important pathogens concurrent with selective inhibition of APRIL signaling through treatment with sibeprenlimab. Preservation of circulating B-cell populations, including memory B cells and plasmablasts, is consistent with the mechanism of sibeprenlimab as a B-cell–nondepleting agent,14 unlike B-cell–targeted therapies such as rituximab that broadly deplete CD20+ B cells.18,33 Dual APRIL/BAFF inhibitors have also been shown to produce significant modulations of B-cell subsets. Povetacicept phase 1 data showed reductions in naive B cells (up to 39%) and antibody-secreting cells (up to 76%) and increases in memory B cells34; phase 1b data in patients with SLE receiving atacicept showed reductions in total B cells and mature B cells35; and a single-center observational study in patients with SLE receiving telitacicept reported reductions in naive B cells (75.7%) and plasmablasts (57.6%).36 Interventions that reduce circulating B cells, especially CD20-directed B-cell depletion, have been associated with weaker humoral responses to vaccination, including SARS-CoV-2 mRNA vaccines.37–39 In multiple sclerosis, greater B-cell depletion during anti-CD20 therapy was associated with impaired SARS-CoV-2 seroconversion after mRNA vaccination.40 Effects of BAFF inhibition on B-cell development have also been associated with impaired vaccine responses.41 At the same time, BAFF inhibition does not universally abrogate vaccine responses because preserved functional antibody generation has been observed with the BAFF-targeted therapy belimumab in a phase 4 trial in SLE.42 A preliminary conference report in IgA nephropathy provides limited context on infection outcomes and vaccine-related immunity with atacicept. COVID-19 events seemed broadly similar between atacicept and placebo groups, and protective diphtheria/tetanus titers were maintained, but the analyses are based on small patient numbers.43 The phase 2 IGNAZ study of the anti-CD38 mAb felzartamab in IgA nephropathy similarly reports preservation of humoral immunity using anti-tetanus toxoid and anti–SARS-CoV-2 antibody assessments in limited evaluable subsets.44 While evidence is still emerging, this study suggests that targeted immunomodulation by sibeprenlimab may offer a tailored treatment approach compared with broader B-cell depletion strategies through more precise modulation of B-cell function and antibody production. Although this substudy was not designed or powered to formally assess the effects of sibeprenlimab on host humoral protective immunity, important and useful data were extracted indicating sibeprenlimab was not associated with any observable risk or severity of symptomatic COVID-19 infection. Because this post hoc analysis was conducted opportunistically owing to the temporal overlap of the COVID-19 pandemic with the ENVISION trial, it has certain limitations. Serologic assessments were conducted in a subset of study participants with monthly sample collection, limiting resolution of immune kinetics and assessment of precise time-resolved titer peaks. Antibody responses were measured against the RBD of the Wuhan strain of SARS-CoV-2, and responses to emerging variants or neutralization capacity were not within the scope of this analysis. The study was not powered for certain statistical analyses, particularly those assessing antibody durability in association with clinical endpoints. This may affect the interpretation of statistical significance because of the risk of potential type 2 error. Adequately powered studies are warranted to further investigate the relationship between antibody titers and viral neutralization, which could not be addressed in the current substudy. In addition, an effect of sibeprenlimab treatment on the response to other antigens cannot be excluded on the basis of this SARS-CoV-2–specific assessment of serologic and salivary antibodies responses. Data within this exploratory substudy indicate that APRIL inhibition with sibeprenlimab achieves a balance between reducing pathogenic Gd-IgA1 and preservation of humoral and mucosal immunity to novel COVID-19 antigens after vaccination and infection. The findings of this post hoc study, combined with the primary analysis of the phase 2 ENVISION trial, suggest that selective APRIL inhibition, such as with sibeprenlimab, offers a targeted and potentially safer alternative to broadly immunosuppressive therapies, which is likely to contribute to preserving kidney function without meaningfully inhibiting protective immune responses to clinically relevant viral pathogens and vaccines. Supplementary Material